Yue Wei, Yunyun Gao, Ruijie Li, Yao Chen, Wenjing Bai, Peirui Zhao, Junchi Hu, Linfeng Li, Xing Wang, Guobing Yin, Yongjun Dang, Xiangqian Kong, Zufeng Guo
2026.2.1Acta Pharmaceutica Sinica B
Abstract
Target-based drug screening typically relies on biochemical or affinity-based assays to identify compounds that modulate or bind to purified target proteins in vitro . However, additional cellular validation is essential to confirm genuine drug-target engagements. Integrating screening and validation within a single cellular assay could greatly expedite the drug discovery process. Herein, we developed a cellular ligand discovery method called CPSEA (cellular protein stability enhancement assay), which leverages the biophysical principle of ligand-induced stabilization of target proteins containing destabilizing mutations. Using CPSEA, we identified arteannuin B and colchicine as novel ligands for FKBP12 and KRAS G12S , respectively. Importantly, we introduced both experimental and computational strategies to identify destabilizing mutations, thereby broadening the applicability of CPSEA for target proteins with and without known stabilizing ligands. Overall, CPSEA represents a powerful cell-based screening strategy with significant potential in target-based drug discovery.
Citation format
WEI, Yue, et al. High-throughput ligand discovery in living cells using the cellular protein stability enhancement assay. Acta Pharmaceutica Sinica B, 2026, 16(7): 4524–4538.